Yesterday, the biotechnology company Capstan Therapeutics launched with $165 million in seed and Series A funding for it to build on its foundational insights into precision in vivo engineering ...

Some maritime special operators are getting a robotic turret that can turn machine guns into an autonomous drone-killer for boats and other vehicles. U.S. Special Operations Command awarded defense ...

London Marine Consultants has continued its run of success in Vietnam with a new contract to provide an external turret mooring system for the Block B floating storage and offloading vessel. Turret ...

Taiwan's National Chung-Shan Institute of Science and Technology (NCSIST) displayed its 2.75 inch Rocket Turret Vehicle system at the Taipei Aerospace & Defense Technology Exhibition (TADTE) 2025 held ...

Acquisition adds a potential first-in-class in vivo targeted lipid nanoparticle (tLNP) anti-CD19 CAR-T therapy candidate for B cell-mediated autoimmune diseases as well as a proprietary tLNP platform ...

AbbVie has agreed to acquire Capstan Therapeutics for up to $2.1bn, adding a “high-risk, high-reward” clinical-stage in vivo CAR-T candidate to its pipeline. Capstan is developing a new type of CAR-T ...

(RTTNews) - Biopharmaceutical company AbbVie, Inc. (ABBV) and privately-held clinical-stage biotechnology company Capstan Therapeutics, Inc., announced Monday a definitive agreement under which AbbVie ...

A tank turret is the brain and brawn of an armored fighting vehicle, housing its most critical functions: the main gun, targeting systems, and a complement of crew. From the outside, it might seem ...

AbbVie is making a full strength play for the in vivo CAR-T market, snapping up Capstan Therapeutics for $2.1 billion to add an early-phase autoimmune drug candidate to its pipeline. Capstan is part ...

(Reuters) -AbbVie said on Monday it would acquire privately held cell therapy developer Capstan Therapeutics in a deal worth up to $2.1 billion, expanding its product pipeline with experimental ...

AbbVie agreed to acquire Capstan Therapeutics, including its lead asset, for $2.1 billion in cash. The North Chicago, Ill., drugmaker's planned acquisition includes CPTX2309, which is currently in ...